Mercado Global de Tratamento do Paraganglioma – Tendências da Indústria e Previsão para 2028

Análise de mercado e insights: Mercado global de tratamento do paraganglioma

Espera-se que o mercado de tratamento do paraganglioma ganhe crescimento a uma taxa potencial de 9,15% no período previsto de 2021 a 2028. O aumento das atividades de investigação e desenvolvimento é o fator responsável pelo crescimento do mercado.

O paraganglioma ou tumores glómicos é um tipo raro de cancro que ocorre em vários locais da cabeça e pescoço ou no ouvido, em certos vasos sanguíneos e nervos fora das glândulas supra-renais. É um cancro neuroendócrino ultra-raro que surge a partir de células chamadas paragânglios. As células paragânglias encontram-se perto de grupos de células nervosas chamados gânglios. A maioria dos paragangliomas tem origem numa das duas glândulas supra-renais situadas acima dos rins, na parte posterior do abdómen superior. Causa uma ativação excessiva das hormonas adrenais que pode causar hipertensão arterial com risco de vida, insuficiência cardíaca e acidente vascular cerebral nestes doentes. Geralmente afeta os pulmões e os rins. Nesta síndrome são produzidos anticorpos contra uma região específica do colagénio nos pulmões e nos rins. 

Espera-se que o rápido aumento da consciencialização das pessoas em relação à doença acelere o crescimento do mercado no período previsto de 2021 a 2028. Da mesma forma, o aumento da designação especial das autoridades reguladoras impulsiona o crescimento do mercado de tratamento do paraganglioma. Além disso, o aumento da prevalência de estilos de vida pouco saudáveis, como o alcoolismo e o tabagismo, o aumento da consciencialização sobre a saúde e os avanços contínuos no tratamento estão a impulsionar a taxa de crescimento do mercado.

Além disso, o aumento das atividades de investigação e desenvolvimento, a elevada adoção de soluções de saúde e a forte presença de um pipeline promissor irão provavelmente criar várias novas oportunidades que terão impacto no crescimento do mercado de tratamento do paraganglioma no período de previsão de 2021 a 2028 .

However, the lack of awareness among people and the limited operating revenue opportunities for research and development of targeted therapies are expected to act as major restraints towards the growth of the paraganglioma treatment market, whereas the lack of healthcare budget in some middle-income countries and the delay in diagnosis of the disease can challenge the growth of the target market in the above mentioned forecast period.

This paraganglioma treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the paraganglioma treatment market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Paraganglioma Treatment Market Scope and Market Size

Paraganglioma treatment market is segmented on the basis of treatment type, site of origin, therapy type, drugs, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment type, the paraganglioma treatment market is segmented into sympathetic and parasympathetic paragangliomas.
• On the basis of site of origin, the paraganglioma treatment market is bifurcated into caroid, cervical, vagal paragangliomas and others.
• On the basis of therapy type, the paraganglioma treatment market is segmented into radiation therapy, chemotherapy, peptide receptor radionuclide therapy and others.
• On the basis of drugs, the paraganglioma treatment market is segregated into iobenguane I 131, cyclophosphamide, vincristine, dacarbazine and others.
• On the basis of route of administration, the paraganglioma treatment market is segmented into oral and injectable.
• Based on end user, the paraganglioma treatment market can be segmented into hospitals, homecare, specialty clinics and others.
• On the basis of distribution channel, the paraganglioma treatment market is segmented into hospital pharmacies, retail pharmacies and others.

Paraganglioma Treatment Market Country Level Analysis

Paraganglioma treatment market is analyzed and market size information is provided by country by treatment type, site of origin, therapy type, drugs, route of administration, end user and distribution channel as referenced above.

The countries covered in the paraganglioma treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America leads the paraganglioma treatment market due to the increase in the prevalence of unhealthy lifestyle. Asia-Pacific region is expected to expand at a significant growth rate in the forecast period of 2021 to 2028 because of the rise in geriatric population, increase in the healthcare awareness and the high adoption of healthcare solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Paraganglioma treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Paraganglioma Treatment Market Share Analysis

Paraganglioma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to paraganglioma treatment market.

Os principais players abrangidos no relatório do mercado de tratamento do paraganglioma são a Progenics Pharmaceuticals, Inc, AstraZeneca, Advanced Accelerator Applications, Jubilant Life Sciences Ltd, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Cipla Inc, Amneal Pharmaceuticals LLC, Amerigen Pharmaceuticals Limited, Jiangsu Hengrui Medicine Co., Ltd, Fresenius Kabi AG e ONO PHARMACEUTICAL CO., LTD e outros, entre outros players nacionais e globais. Os dados de quota de mercado do tratamento do paraganglioma estão disponíveis para a global, América do Norte, América do Sul, Europa, Ásia-Pacífico (APAC) e Médio Oriente e África (MEA) separadamente. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-46440